Contract Research & Services
Today in Contract Research & Services

Contract Research & Services

Merck to invest $125m in Moderna Therapeutics Merck has agreed to invest $125m in Moderna Therapeutics under a new agreement that expands the firms’ 2016 partnership to develop messenger RNA (mRNA) cancer vaccines. Contract Research & Services > Clinical Trials > News

Latest Contract Research & Services News by Sector

Select a sector from the list or browse by sector below:

Clinical Trials

Pfizer’s Lyrica meets primary endpoint in phase 3 pediatric epilepsy trial
Pfizer has reported positive top-line results from a phase 3 study, which assessed the use of Lyrica (pregabalin) oral solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.
Contract Research & Services > Clinical Trials > News
IDMC recommends to expand Tiziana’s phase 2a trial of Milciclib
Tiziana Life Sciences announces that the independent data monitor committee (IDMC) completed a second, interim analysis of tolerability data from the first eleven treated patients and recommended expansion of the initial cohort to continue enrolment of an additional 20 patients to complete the trial.
Contract Research & Services > Clinical Trials > News

Contract Research

RXi Pharmaceuticals enters into research collaboration with Iovance Biotherapeutics
RXi Pharmaceuticals has partnered with Iovance Biotherapeutics to evaluate its sd-rxRNA therapeutic compounds with the latter’s autologous cell therapy based on tumor-infiltrating lymphocytes (TILs) for the use in the treatment of cancer.
Contract Research & Services > Contract Research > News
NetVation DL Medicine enters into research collaboration with Pfizer
Chinese biotechnology company NetVation DL Medicine, which is focused on the discovery and development of novel drug candidates, has entered into a two-year research collaboration with Pfizer.
Contract Research & Services > Contract Research > News

Contract Services

Mylan to buy global marketing rights of Mapi’s Glatiramer acetate product
Mylan has agreed to acquire global marketing rights of Israel-based Mapi Pharma’s GA Depot, a long-acting once-monthly Glatiramer acetate product.
Contract Research & Services > Contract Services > News
Ionis licenses to Akcea global rights to inotersen in $1.7bn deal
By PBR Staff Writer
Ionis Pharmaceuticals has licensed to Akcea Therapeutics worldwide rights to inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction potentially worth about $1.7bn.
Contract Research & Services > Contract Services > News